Fresenius Steps Up International Ambition Through Akorn Pursuit
Executive Summary
German healthcare company Fresenius SE & Co. pursues a second major international deal in less than year, as new CEO confirms interest in US generics firm Akorn.
You may also be interested in...
Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy
Fresenius is shoring up its near-term US growth prospects by acquiring generics firm Akorn, as well boosting its future outlook by entering the biosimilars space via a deal with Merck KgaA.
Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy
Fresenius is shoring up its near-term US growth prospects by acquiring generics firm Akorn, as well boosting its future outlook by entering the biosimilars space via a deal with Merck KgaA.
GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate
Firms could find themselves charged multiple US generic drug user fees if affiliates are not identified and ANDAs claimed.